The global Human Embryonic Stem Cells market size was valued at USD 494.7 million in 2015. These are the pluripotent cells that possess the ability to get differentiated into all germ layers. Rising demand owing to the increasing incidence of genetic disorders is anticipated to boost growth.
Research carried out in order to utilize them for disease eradication is expected to support projected growth. Controlled differentiation that can be achieved in tissue committed cells through the co-culturing with basic fibroblast growth factor is expected to induce growth.
UK human embryonic stem cells market, by application, 2014-2025 (USD Million)
Active involvement of the organizations for developing alternative ways of production of hESCs is anticipated to drive progress. For instance, Science University and Oregon Health are engaged in developing blastocyst staged embryos of around 150 cells in order to provide hESC source.
Stem cells derived through such techniques can be converted into liver, nerve, and heart tissues. Although this requires significant R&D for implementation as safe and effective treatment options, these can be applied in developing biologics for regenerative medicine.
Moreover, implementation of ESC based animal models in the academic institutes serves a considerably important role for projected growth. In 2014, 70% of trials were sponsored by academic institutions and 30% by the private sector.
Rapid advancements in this vertical include protocols for directed differentiation, defined culture systems, demonstration of applications in drug screening, the establishment of various disease models, and evaluation of therapeutic potential in treating incurable diseases.
The advantages associated with their use are projected to boost the demand in the research community. These advantages include the presence of pluripotent markers, the production of high levels of telomerase, and the ability to be coaxed into a whole battery of tissue types.
Accelerated uptake of ESC based cell therapy on in vivo and in vitro principle is expected to fuel growth through to 2024. Research carried out to reduce the problems of immunogenicity and teratoma induction is expected to drive R&D in industry.
However, implementation remains a controversial topic due to diverse views in context to the moral and legal status of early embryo cell lines. This has led to conflicting and provocative claims inside and outside the scientific community pertaining to their biomedical potential.
Human embryonic stem cells market, by region, 2015 (USD Million)
Applicability for inducing differentiation into a wide range of tissues is attributive to the largest share of regenerative medicine. The differentiated cells are further used for therapeutic applications in regenerative medicine.
hESC research is anticipated to have considerable potential in the treatment of disorders wherein cellular loss is known to occur. These disorders include Parkinson's disease, post-myocardial infarction, lung disorders, and Type 1 diabetes mellitus.
Furthermore, the unique properties of hESC based models enable them to revolutionize the earliest steps of drug discovery. Particularly, pathological and toxicology modeling can be performed by the provision of physiological models for different human cell types.
Variation in the policies across the globe is expected to impact the global human embryonic stem cell market development. North America dominated the market with respect to revenue generation as a result of the presence of several prominent entities incorporated in the U.S.
As hESC research is permitted in Belgium, Finland, UK, Denmark, Sweden, and the Netherlands, Europe is estimated to follow North America in revenue generation. Moreover, the government of Asian countries is supportive of hESC research thus boosting growth in this region.
Significant involvement of the Japanese government in the development of cell line based therapies is a significant factor and is expected to provide lucrative growth avenues. The presence of government-backed efforts to create a bank of iPSC lines is attributive to drive progress.
Some of the prominent players operating in this vertical include Thermo Fisher Scientific, Inc.;
CellGenix GmbH, ESI BIO, PromoCell GmbH, Lonza, Kite Pharma, LifeCell, and International Stem Cell Corporation.
Most of these companies are engaged in strategic endeavors in order to maintain market share. For instance, Astella Therapeutics acquired Ocata Therapeutics which is anticipated to enhance its presence with respect to cell therapy.
The players are also involved in portfolio expansion by the introduction of culture media that is designed to optimize the expansion rate of hESC. Presence of products in clinical trials attributive to influence progress.
Base year for estimation
Actual estimates/Historical data
2014 & 2015
2016 - 2025
Revenue in USD Million and CAGR from 2016 to 2025
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
U.S., Canada, UK, Germany, Japan, China, Brazil, South Africa.
Revenue forecast, company share, competitive landscape, growth factors and trends
15% free customization scope (equivalent to 5 analyst working days)
If you need specific market information, which is not currently within the scope of the report, we will provide it to you as a part of customization
This report forecasts revenue growth at the regional & country level and provides an analysis of the latest trends and opportunities in each of the sub-segments from 2014 to 2025. For the purpose of this report, Grand View Research has segmented the human embryonic stem cells market on the basis of application and regions:
Application Outlook (Revenue, USD Million; 2014 - 2025)
Stem cell biology research
Regional Outlook (Revenue, USD Million; 2014 - 2025)
Middle East and Africa (MEA)
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
"The quality of research they have done for us has been excellent."